

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr ALPHAGAN P®

brimonidine tartrate ophthalmic solution

Solution, 0.15% w/v, for ophthalmic use

Relatively Selective α_2 -Adrenoceptor Agonist

ATC code: S01EA05

AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Quebec
H4S 1Z1

Date of Initial Authorization:
NOV 04, 2003

Date of Revision:
AUG 25, 2022

Submission Control Number: 266495

RECENT MAJOR LABEL CHANGES

None at the time of the most recent authorization.

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	4
4.4 Administration	5
4.5 Missed Dose	5
5 OVERDOSAGE	5
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	5
7 WARNINGS AND PRECAUTIONS	6
7.1 Special Populations	7
7.1.1 Pregnant Women	7
7.1.2 Breast-feeding.....	7
7.1.3 Pediatrics.....	7
7.1.4 Geriatrics.....	7
8 ADVERSE REACTIONS	8
8.1 Adverse Reaction Overview	8
8.2 Clinical Trial Adverse Reactions	8
8.2.1 Clinical Trial Adverse Reactions – Pediatrics.....	9
8.5 Post-Market Adverse Reactions.....	10
9 DRUG INTERACTIONS	10

9.2	Drug Interactions Overview	10
9.3	Drug-Behavioural Interactions.....	10
9.4	Drug-Drug Interactions	10
9.5	Drug-Food Interactions.....	11
9.6	Drug-Herb Interactions	11
9.7	Drug-Laboratory Test Interactions.....	11
10	CLINICAL PHARMACOLOGY	11
10.1	Mechanism of Action	11
10.2	Pharmacodynamics.....	12
10.3	Pharmacokinetics.....	13
11	STORAGE, STABILITY AND DISPOSAL.....	14
12	SPECIAL HANDLING INSTRUCTIONS.....	14
PART II: SCIENTIFIC INFORMATION		15
13	PHARMACEUTICAL INFORMATION	15
14	CLINICAL TRIALS	16
14.1	Clinical Trials by Indication	16
	Control of Intraocular Pressure	16
15	MICROBIOLOGY	18
16	NON-CLINICAL TOXICOLOGY	18
PATIENT MEDICATION INFORMATION		21

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

ALPHAGAN P® (brimonidine tartrate) is indicated for:

- the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

1.1 Pediatrics

Pediatrics (< 18 years of age): The safety and efficacy of ALPHAGAN P has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. See 2 CONTRAINDICATIONS, 7.1.3 Pediatrics, and 8.2.1 Clinical Trial Adverse Reactions – Pediatrics.

1.2 Geriatrics

Geriatrics (> 65 years of age): No overall difference in safety and effectiveness has been observed between elderly and other adult patients.

2 CONTRAINDICATIONS

ALPHAGAN P is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTH, COMPOSITION AND PACKAGING.
- Patients receiving monoamine oxidase (MAO) inhibitor therapy.
- Neonates and infants (children under the age of 2 years).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Patients should be advised that if they have ocular surgery or develop any type of ocular condition, they should immediately seek their doctor's advice concerning the continued use of the present bottle.

4.2 Recommended Dose and Dosage Adjustment

- The recommended dose is one drop of ALPHAGAN P in the affected eye(s) three times daily (TID), approximately 8 hours apart.

Health Canada has not authorized an indication for pediatric use.

4.4 Administration

Do not allow the dropper tip of the bottle to touch the eye or other surrounding structures, because this could cause eye injury or contaminate the tip with common bacteria known to cause eye infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients Wearing Soft Contact Lenses:

Lenses should be removed prior to the application of ALPHAGAN P and not re-inserted earlier than 15 minutes after administration.

4.5 Missed Dose

A missed dose should be applied as soon as the patient remembers. The regular dosing schedule should then be resumed with the next dose. Patients should not apply more than one dose at a time in an effort to catch up on missed doses.

5 OVERDOSAGE

In ophthalmic overdose cases that have been received, the events reported have generally been those already listed as adverse reactions.

Systemic overdose resulting from accidental ingestion:

There is very limited information regarding accidental ingestion of brimonidine in adults. The only adverse event reported to date was hypotension. Treatment of an oral overdose includes supportive and symptomatic therapy; a patient's airway should be maintained. Evacuation of the stomach should be considered during the first few hours after an overdose.

Symptoms of brimonidine overdose such as apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in neonates, infants, and children receiving ALPHAGAN® as part of medical treatment of congenital glaucoma or by accidental oral ingestion. See [2 CONTRAINDICATIONS](#).

For management of a suspected drug overdose, including accidental ingestion, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Ophthalmic	Solution, 0.15% w/v	Contains PURITE® 0.005% w/v (Stabilized Oxychloro Complex [from chlorite, chlorate and chlorine dioxide]) as preservative, boric acid, calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, purified water with hydrochloric acid or sodium hydroxide to adjust the pH, sodium borate decahydrate, sodium carboxymethylcellulose

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
		and sodium chloride. The pH range of ALPHAGAN P solution is 6.6 to 7.4.

ALPHAGAN P is sterile and supplied in 5 mL and 10 mL teal, opaque plastic dropper bottles with a purple cap.

7 WARNINGS AND PRECAUTIONS

General

FOR TOPICAL OPHTHALMIC USE ONLY.

Carcinogenesis and Mutagenesis

No compound-related carcinogenic effects were observed in 21 month and 2 year studies in mice and rats given oral doses of 2.5 mg base/kg/day and 1.0 mg base/kg/day of brimonidine tartrate, respectively. These doses achieved 106 and 145 times, respectively, the plasma drug concentration estimated in humans treated with one drop of ALPHAGAN P into both eyes TID.

Brimonidine was not mutagenic or cytogenic in a series of in vitro and in vivo studies including the Ames test, host-mediated assay, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, cytogenic studies in mice and the dominant lethal assay.

Cardiovascular

Although ALPHAGAN P had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients receiving ALPHAGAN P with severe cardiovascular disease.

ALPHAGAN P should be used with caution in patients with cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.

Driving and Operating Machinery

ALPHAGAN P, as with other similar medications, can potentially cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.

ALPHAGAN P may also cause blurred vision or visual disturbance in some patients. The patient should wait until these symptoms have cleared before driving or using machinery.

Hepatic/Biliary/Pancreatic

ALPHAGAN P has not been studied in patients with hepatic impairment; caution should be exercised in treating such patients.

Psychiatric

ALPHAGAN P should be used with caution in patients with depression.

Renal

ALPHAGAN P has not been studied in patients with renal impairment; caution should be exercised in treating such patients.

Sensitivity/Resistance

ALPHAGAN P should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists.

7.1 Special Populations

7.1.1 Pregnant Women

Teratogenicity studies showed no adverse effects in rats and rabbits when oral doses (1.65 mg base/kg/day and 3.33 mg base/kg/day of brimonidine tartrate, respectively) were administered during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. These doses achieved AUC values 258- and 17-fold higher, respectively, than similar values estimated in humans treated with ALPHAGAN P given as one drop in both eyes TID.

There are no studies of ALPHAGAN P in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent (ratio of drug-related material in fetal:maternal blood = 0.1 - 0.3). Drug-derived material was eliminated from fetal tissues by 24 hours post-dose. ALPHAGAN P should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

7.1.2 Breast-feeding

Studies in rats have indicated brimonidine is excreted in the milk of the lactating rat. Since it is not known whether this drug is excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

7.1.3 Pediatrics

Neonates and infants (children under the age of 2 years): The use of ALPHAGAN P in neonates and infants is contraindicated. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% to infants in the age range of 28 days to 3 months. See [2 CONTRAINDICATIONS](#) and [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#).

Children (2-18 years of age): The use of ALPHAGAN P is currently **not recommended** in children, as several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in the pediatric population. See [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#).

7.1.4 Geriatrics

No overall difference in safety and effectiveness has been observed between elderly and other adult patients. The C_{max} and apparent half-life of brimonidine tartrate were similar in elderly subjects (65 years or older) and younger adults, indicating that its systemic absorption and elimination were not significantly affected by age.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

In the two 12-month Phase 3 clinical studies conducted with ALPHAGAN P, the most commonly reported adverse drug reactions overall were conjunctival hyperemia (18.2%), allergic conjunctivitis (9.2%), eye pruritus (8.2%), visual disturbance (6.1%), conjunctival folliculosis (5.5%), burning sensation in the eye (5.3%), and oral dryness (5.3%). Most treatment-related adverse events were ocular and were mild or moderate. Serious adverse events (AEs) were reported for 8.9% of patients treated with ALPHAGAN P. All of the serious AEs were judged to be unrelated to study treatment. The most common adverse event leading to study discontinuation was allergic conjunctivitis in 7.4% of patients treated with ALPHAGAN P.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Table 2 – Treatment-Related Adverse Reactions Occurring at ≥ 1% with ALPHAGAN P

	Brimonidine- PURITE 0.15% n = 380 (%)	Brimonidine- PURITE 0.2% n = 383 (%)	ALPHAGAN n = 383 (%)
Eye disorders			
conjunctival hyperemia	69 (18.2%)	81 (21.1%)	98 (25.6%)
allergic conjunctivitis	35 (9.2%)	56 (14.6%)	60 (15.7%)
eye pruritus	31 (8.2%)	42 (11.0%)	45 (11.7%)
visual disturbance	23 (6.1%)	28 (7.3%)	30 (7.8%)
conjunctival folliculosis	21 (5.5%)	28 (7.3%)	31 (8.1%)
burning sensation in the eye	20 (5.3%)	28 (7.3%)	32 (8.4%)
eye dryness	11 (2.9%)	19 (5.0%)	17 (4.4%)
foreign body sensation	11 (2.9%)	13 (3.4%)	20 (5.2%)
epiphora	10 (2.6%)	13 (3.4%)	18 (4.7%)
eyelid edema	8 (2.1%)	13 (3.4%)	9 (2.3%)
eye pain	7 (1.8%)	11 (2.9%)	10 (2.6%)
blepharitis	6 (1.6%)	1 (0.3%)	6 (1.6%)
erythema eyelid	6 (1.6%)	9 (2.3%)	9 (2.3%)
irritation eye	6 (1.6%)	5 (1.3%)	12 (3.1%)
ocular stinging sensation	6 (1.6%)	1 (0.3%)	6 (1.6%)

	Brimonidine- PURITE 0.15% n = 380 (%)	Brimonidine- PURITE 0.2% n = 383 (%)	ALPHAGAN n = 383 (%)
photophobia	6 (1.6%)	0 (0.0%)	4 (1.0%)
conjunctival edema	5 (1.3%)	5 (1.3%)	6 (1.6%)
eye discharge	5 (1.3%)	7 (1.8%)	15 (3.9%)
follicular conjunctivitis	5 (1.3%)	3 (0.8%)	3 (0.8%)
superficial punctate keratitis	5 (1.3%)	2 (0.5%)	3 (0.8%)
visual acuity worsened	4 (1.1%)	3 (0.8%)	4 (1.0%)
Gastrointestinal			
oral dryness	20 (5.3%)	36 (9.4%)	40 (10.4%)
General disorders and administration site conditions			
Asthenia	6 (1.6%)	8 (2.1%)	16 (4.2%)
Nervous system disorders			
headache	9 (2.4%)	7 (1.8%)	7 (1.8%)
Respiratory, thoracic and mediastinal disorders			
rhinitis	4 (1.1%)	2 (0.5%)	1 (0.3%)

In clinical studies the most frequently reported adverse reactions (>1%) classified as treatment-related from the 12 month Phase III controlled clinical studies for patients (n = 380) who received ALPHAGAN P are listed in Table 2. Adverse events were coded using the COSTART dictionary available at the time of the study but are presented in Table 2 using MedDRA System Organ Class.

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

In a 3-month, phase 3 study in children aged 2-7 years with glaucoma, inadequately controlled by beta-blockers, a high prevalence of somnolence (55%) was reported with ALPHAGAN 0.2% as adjunctive treatment. In 8% of children, this was severe and led to discontinuation of treatment in 13%. The incidence of somnolence decreased with increasing age, being least in the 7-year-old age group (25%), but was more affected by weight, occurring more frequently in those children weighing ≤ 20 kg (63%) compared to those weighing > 20 kg (25%).

The safety and effectiveness of ALPHAGAN P has not been studied in children under the age of two years. During post-marketing surveillance, somnolence, lethargy, hypotonia, hypothermia, bradycardia, hypotension, apnoea, respiratory depression, pallor and coma have been reported in neonates, infants and children receiving brimonidine either for congenital glaucoma or via accidental ingestion. See [2 CONTRAINDICATIONS](#) and [7.1.3 Pediatrics](#).

8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post-marketing use of ALPHAGAN P in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

Eye disorders: vision blurred, conjunctivitis

General disorders and administration site conditions: fatigue

Immune system disorders: hypersensitivity

Nervous system disorders: dizziness, somnolence

The following adverse reactions have been identified during post-marketing use of ALPHAGAN in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

Cardiac disorders: palpitations/arrhythmias (including bradycardia or tachycardia)

Eye disorders: iritis, iridocyclitis (anterior uveitis), miosis, conjunctivitis, eyelids pruritus

Immune system disorders: hypersensitivity

Nervous system disorders: syncope

Psychiatric disorders: depression

Skin and subcutaneous tissue disorders: skin reaction

Vascular disorders: hypotension

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

ALPHAGAN P did not have clinically significant effects on pulse and blood pressure in chronic clinical studies. However, since alpha-agonists, as a class, may reduce pulse and blood pressure, caution in the concomitant use of drugs such as beta-blockers (ophthalmic and/or systemic), antihypertensives, and/or cardiac glycosides is advised.

9.3 Drug-Behavioural Interactions

No formal drug-behavioural interaction studies were conducted with ALPHAGAN P.

9.4 Drug-Drug Interactions

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN P can lead to an interference in intraocular pressure (IOP) lowering effect. No data are available on the level of circulating catecholamines after ALPHAGAN P is instilled. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants (e.g., alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Brimonidine tartrate is a relatively selective alpha-2-adrenergic receptor agonist that, in radioligand binding assays and in functional assays, is approximately 1000 times more selective for the alpha-2 adrenoceptor than the alpha-1 adrenoceptor. This selectivity results in the absence of vasoconstriction in microvessels associated with human retinal xenografts.

Topical administration of brimonidine decreases IOP in humans. When used as directed, brimonidine tartrate ophthalmic solutions reduce elevated IOP with minimal effect on cardiovascular parameters.

Brimonidine tartrate has a rapid onset of action, with the peak ocular hypotensive effect occurring at approximately two hours post-dosing. The duration of effect is 12 hours or greater.

Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action. ALPHAGAN P lowers IOP by reducing aqueous humor production and increasing uveoscleral outflow.

The effect of brimonidine on aqueous humour dynamics was determined in 21 ocular hypertensive patients. Measurements were made at baseline and following one week (Day 8) of twice daily (BID) application of one drop of brimonidine tartrate 0.2% to one eye and vehicle to the other eye, in a double-blind fashion. The results of this study (mean \pm SEM) are reported in Table 3. They indicate that brimonidine reduces IOP in humans by decreasing aqueous inflow and increasing uveoscleral outflow.

Table 3 – Effects of Brimonidine on Aqueous Humour Dynamics

	Control Eye		Treated Eye	
	Baseline	Day 8	Baseline	Day 8
IOP	21.3 \pm 1.0	20.0 \pm 0.6*	20.6 \pm 0.8	15.9 \pm 0.6*†
Fa	2.6 \pm 0.2	2.3 \pm 0.1*	2.5 \pm 0.2	2.0 \pm 0.1*
Fu _{fil}	0.35 \pm 0.20	0.50 \pm 0.17	0.12 \pm 0.28	0.65 \pm 0.16*
Fu _{ton}	0.28 \pm 0.31	0.08 \pm 0.35	0.25 \pm 0.37	1.02 \pm 0.11*†
C _{fl}	0.22 \pm 0.03	0.16 \pm 0.02*	0.22 \pm 0.03	0.21 \pm 0.03
C _{ton}	0.17 \pm 0.01	0.19 \pm 0.02	0.19 \pm 0.03	0.16 \pm 0.02
Pev	8.9 \pm 0.5	8.5 \pm 0.4	8.8 \pm 0.5	9.2 \pm 0.3

* $p \leq 0.05$ vs baseline
† $p \leq 0.05$ vs control

	Control Eye		Treated Eye	
	Baseline	Day 8	Baseline	Day 8
Fa = aqueous flow (mL/min) C _{fi} = outflow capacity (mL/min/mmHg) IOP = intraocular pressure (mmHg) C _{ton} = tonographic outflow facility (mL/min/mmHg) P _{ev} = episcleral venous pressure (mmHg) F _{u_{fi}} = uveoscleral outflow by fluorophotometry (mL/min) F _{u_{ton}} = uveoscleral outflow by tonography (mL/min)				

10.2 Pharmacodynamics

ALPHAGAN P has no effect on pulmonary function or exercise-induced tachycardia. The cardiovascular effects of ALPHAGAN P during exercise in normal volunteers were found to be limited to a slight suppression of systolic blood pressure, which was clinically insignificant, during the recovery period following a treadmill test.

In short-term studies (up to four days) in normal healthy volunteers, brimonidine tartrate ophthalmic solutions preserved with benzalkonium chloride lowered IOP significantly better than vehicle at all concentrations tested (0.02 - 0.5%) and was found to be safe and comfortable. At these concentrations, the peak effect on IOP was observed between one and four hours post-instillation. The greatest reduction in IOP was dose-related, reaching a maximal decrease from baseline of up to 40% with brimonidine tartrate 0.5%. In the morning (12 hours after the evening instillation), the 0.08% and 0.2% concentrations reached a maximal IOP lowering effect following two days of BID dosing. This was observed with the 0.5% concentration, 12 hours after the first instillation. Conjunctival blanching was observed primarily at the 0.35% and 0.5% concentrations, and was generally mild or moderate in nature. There was a significantly greater incidence of dry eye seen only with brimonidine tartrate 0.5% as compared to vehicle, although this finding was also reported at the lower concentrations. The overall mean decrease in pupil size and systolic blood pressure was generally greater with brimonidine 0.2% and 0.5% than with vehicle. This change in systolic blood pressure was not judged to be clinically significant. Heart rate, diastolic blood pressure, visual acuity and cup-disc ratio did not appear to be significantly affected by brimonidine treatment (as compared to vehicle). Additionally, at the concentrations tested in these healthy volunteer studies, a contralateral effect of brimonidine was not observed.

When evaluated in open-angle glaucoma and ocular hypertensive patients at concentrations of 0.08%, 0.2% and 0.5% for one month (BID), brimonidine tartrate was found to be both efficacious and safe. All concentrations tested were significantly more effective than vehicle in lowering elevated IOP. The two higher concentrations of brimonidine tartrate were also more effective than the 0.08% concentration. Brimonidine tartrate 0.5%, however, was not any more effective than 0.2% for long-term treatment. The peak effect on IOP occurred at two hours for brimonidine tartrate 0.08%, 0.2%, and 0.5%. The greatest decrease in IOP was dose-related, with a maximum reduction of 27% from baseline with brimonidine tartrate 0.2%, and 31% from baseline with brimonidine tartrate 0.5%. Brimonidine tartrate 0.5% was associated with a greater incidence of side effects than brimonidine tartrate 0.2% and 0.08%, including blurring, foreign body sensation, fatigue and drowsiness. Dry mouth was seen more often in all active treatment groups than in the vehicle group. This event was also seen at a higher incidence with brimonidine tartrate 0.5% than with brimonidine tartrate 0.08%. Although heart rate did not appear to be significantly affected by brimonidine treatment, diurnal measurements of blood pressure indicated that brimonidine tartrate 0.5% was associated with a greater decrease than was vehicle or

the lower brimonidine strengths. The mean blood pressure decreases observed were not considered to be clinically significant.

Two 1-month, dose-response studies (n = 222) were conducted to evaluate the efficacy and safety of Brimonidine-PURITE, dosed either BID or TID, compared with ALPHAGAN, Timoptic®, and vehicle. Brimonidine-PURITE 0.1% and 0.2% lowered IOP significantly, compared to vehicle when dosed BID or TID. However, Brimonidine- PURITE 0.1% was less effective than Brimonidine-PURITE 0.2%, ALPHAGAN, or Timoptic, regardless of its dosing regimen. Both Brimonidine-PURITE 0.1% and 0.2% demonstrated acceptable safety profiles.

10.3 Pharmacokinetics

Table 4 – Summary of Brimonidine Pharmacokinetic Parameters in Healthy Volunteers

	C_{max} (ng/mL)	T_{max} (hr)	t_½ (hr)	AUC_{0-8hr}
	0.1%			
TID for 7 days mean	0.03	1.5	1.88	0.136
	0.2%			
TID for 7 days mean	0.0647	1.35	1.95	0.245

Absorption

After ocular administration of Brimonidine-PURITE ophthalmic solution 0.1% or 0.2% (brimonidine tartrate 0.1% or 0.2% preserved with PURITE), plasma concentrations peaked within 0.5 to 2.5 hours, and declined with a systemic half-life of approximately 2 hours.

Plasma brimonidine concentrations and serum glucose concentrations during brimonidine tartrate treatment TID were investigated in a single-center, randomized, double-masked, vehicle-controlled, parallel study of 0.1% and 0.2% brimonidine tartrate ophthalmic solution preserved with PURITE in healthy subjects. Concentration-time profiles of brimonidine were assessed on days 1 and 7.

Plasma brimonidine concentrations were proportional to dose, and during treatment with 0.2% brimonidine tartrate ophthalmic solution preserved with PURITE, were comparable to those measured during treatment with brimonidine tartrate ophthalmic solution preserved with benzalkonium chloride (ALPHAGAN). Plasma C_{max} during TID treatment with ALPHAGAN P (brimonidine tartrate) ophthalmic solution 0.15% are expected to be approximately 47.4 pg/mL, compared to 58.5 pg/mL during BID treatment with ALPHAGAN. Systemic accumulation was minimal. Brimonidine did not affect systemic glucose disposition or serum glucose levels.

Systemic absorption of brimonidine after ocular administration of a single dose (both eyes) of brimonidine tartrate 0.08%, 0.2% and 0.5% to healthy volunteers, produced dose-dependent increases in C_{max} and AUC. AUC increased proportionally with dose between the 0.08% and 0.2% doses; the increase in AUC of the 0.5% dose was less than proportional with the increase in dose. Following the 0.5% dose, plasma C_{max} and AUC₀₋₄ were approximately 0.1 ng/mL and 0.5 ng·hr/mL, respectively. The mean T_{max} was 2 - 3 hours for all concentrations tested in this study. In general, plasma concentrations

declined to undetectable levels by 12 hours post-dose. The apparent plasma $t_{1/2}$ ranged from 2 to 5 hours (mean = 3.3 hours).

Metabolism

Brimonidine is metabolized primarily by the liver.

Elimination

In humans, brimonidine is eliminated rapidly via extensive systemic metabolism. There is no marked systemic accumulation after multiple dosing. Urinary excretion is the major route of elimination of the drug and its metabolites. Approximately 87% of an orally-administered radioactive dose was eliminated within 120 hours, with 74% found in the urine.

Special Populations and Conditions

- **Geriatrics:** Plasma concentration-time profiles were similar for both young and elderly healthy volunteers following ocular instillation of a single dose of brimonidine tartrate 0.2%, although the elderly subjects showed a tendency to have a slightly greater systemic exposure to brimonidine. Steady state concentrations were reached by day 7 of multiple dosing (both eyes, BID) in young (23 - 39 years) subjects. Twice daily ocular dosing for 10 days did not change the systemic absorption and disposition parameters of brimonidine in young subjects. The mean C_{max} was 0.0585 ng/mL and mean AUC_{0-12} was 0.309 ng·hr/mL after multiple dosing. There was a slight systemic drug accumulation after repeated dosing (accumulation factor: 1.4), consistent with an apparent half-life of 3 hours. Beyond 12 hours after the final dose, plasma concentrations were undetectable or approached the limit of quantitation. Systolic and diastolic blood pressures were generally lowered by brimonidine tartrate administration. These decreases in blood pressure tended to be slightly greater among the elderly subjects than among the young subjects.

11 STORAGE, STABILITY AND DISPOSAL

ALPHAGAN P should be stored at 15 to 25°C. Discard unused solution at the end of treatment.

Keep out of sight and reach of children.

12 SPECIAL HANDLING INSTRUCTIONS


Patients should be advised to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution. Refer to [4.4 Administration](#) for more detailed information.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	Brimonidine tartrate
Chemical name:	5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate
Molecular formula and molecular mass:	$C_{11}H_{10}BrN_5 \cdot C_4H_6O_6$ and 442.24 g/mol
Structural formula:	



Physicochemical properties:	Brimonidine tartrate is an off-white, pale yellow to pale pink powder, with a melting point range of 202 - 210°C. It is water soluble (34 mg/mL) and soluble in DMSO (>60 mg/mL), slightly soluble in propylene glycol (~1.0 mg/mL), and very slightly soluble in ethanol (0.6 mg/mL) and acetone (<0.2 mg/mL). The pH of a 1% solution of brimonidine tartrate in water is 3.5 at room temperature. A pK_a value of 7.78 ± 0.05 has been determined.
-----------------------------	---

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Control of Intraocular Pressure

Table 5 – Summary of patient demographics for clinical trials in the control of intraocular pressure

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)		Mean age (Range)	Sex
			No. Entered	No. Completed		
190342-007	Multicenter, double-masked, randomized, active-controlled, parallel study in patients with OAG or OHT	One drop (~35 mcl) in each eye three times daily 12 months	593	398 ALPHAGAN P 0.15% = 131 ALPHAGAN P 0.2% = 135 ALPHAGAN = 132	61.4 (25-93)	43.8% /56.2 %
190342-008	Multicenter, double-masked, randomized, active-controlled, parallel study in patients with OAG or OHT	One drop (~35 mcl) in each eye three times daily 12 months	554	344 ALPHAGAN P 0.15% = 117 ALPHAGAN P 0.2% = 110 ALPHAGAN = 117	65.3 (22.90)	43.0% /57.0 %
Note: OAG = open-angle glaucoma, OHT = ocular hypertension						

Two clinical studies (n = 1,147) lasting for twelve months were conducted to evaluate the safety, efficacy, and acceptability of ALPHAGAN P and 0.2% Brimonidine-PURITE compared with brimonidine tartrate ophthalmic solution 0.2% preserved with benzalkonium chloride (ALPHAGAN), administered TID in patients with glaucoma or ocular hypertension. The IOP values for the Baseline and Month-12 time points using ALPHAGAN P and ALPHAGAN, are summarized in [Table 6](#) below.

Table 6 – Results of studies 190342-007 and 190342-008 in the control of intraocular pressure - Intraocular pressure values (mm Hg) phase 3 studies (ITT LOCF analysis)

		Study 190342-007		Study 190342-008		
		ALPHAGAN P (0.15%) n = 197	ALPHAGAN (0.2%) n = 199	ALPHAGAN P (0.15%) n = 184	ALPHAGAN (0.2%) n = 184	
Baseline	Hour-0					
	Mean	24.9	24.7	24.9	25.3	
	Hour-2					
	Mean	23.1	23.0	23.6	24.1	
	Hour-7					
	Mean	21.8	21.9	22.4	23.0	
	Hour-9					
	Mean	21.7	21.6	22.4	23.1	
Month-12	Hour-0					
	Mean (mean change from baseline)	21.6 (-3.3)	21.3 (-3.4)	22.3 (-2.6)	22.7 (-2.6)	
	CI ^a	(-0.61, 1.01)		(-1.44, 0.45)		
	Hour-2					
	Mean (mean change from baseline)	18.6 (-4.5)	18.1 (-4.9)	19.3 (-4.3)	19.3 (-4.8)	
	CI ^a	(-0.35, 1.16)		(-0.62, 1.09)		
	Hour-7					
	Mean (mean change from baseline)	19.9 (-1.9)	19.6 (-2.3)	20.4 (-2.0)	21.0 (-2.0)	
	CI ^a	(-0.59, 0.92)		(-1.09, 0.58)		
	Hour-9					
	Mean (mean change from baseline)	17.9 (-3.8)	17.4 (-4.2)	18.5 (-3.9)	18.5 (-4.6)	
	CI ^a	(-0.27, 1.18)		(-0.41, 1.29)		
	a = 95% confidence interval for difference between ALPHAGAN P and ALPHAGAN concentrations					
	NOTE:					
	n = number of patients at baseline					
CI = confidence interval						
There was no statistical significance between ALPHAGAN P and ALPHAGAN for within group analysis of changes from baseline using a paired t-test (at all time points the p-value was < 0.001)						

Brimonidine tartrate lowers IOP with minimal effect on cardiovascular parameters (heart rate, systolic and diastolic blood pressure) and no apparent effect on pulmonary parameters (spirometry, respiratory rate).

Efficacy analyses from these two clinical trials indicated that ALPHAGAN P is non-inferior to ALPHAGAN and effectively lowered IOP in patients with glaucoma or ocular hypertension (mean values of at least 2.6 mm Hg at trough, and at least 4.3 mm Hg at peak) over the twelve months of the study. ALPHAGAN P was well tolerated, rated as comfortable by the majority of patients, and provided a superior safety profile when compared with ALPHAGAN. Among the most commonly reported adverse events ($\geq 3.9\%$ incidence) in the ALPHAGAN P group, the frequency of reports were generally fewer than with ALPHAGAN. There was a significantly smaller percentage of patients who experienced allergic conjunctivitis, oral dryness, asthenia, or somnolence in the ALPHAGAN P group.

ALPHAGAN P was the lowest effective dose of brimonidine tartrate with the most favorable safety and tolerability profile.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity

The acute median lethal dose (LD₅₀) or minimum lethal dose (MLD) values of brimonidine were evaluated in mice, rats, rabbits, and dogs by oral and intravenous (i.v.) administration. The LD₅₀ or MLD values for each study are listed below:

Species	Route	LD ₅₀ (mg/kg)*	MLD (mg/kg)*
Mouse	oral	50	>8**
	i.v.*	50	Not performed
Rat	oral	100	>8**
	i.v.	100-150	Not performed
Rabbit	oral	Not performed	>6
	i.v.	Not performed	20-50
Dog	oral	Not performed	0.5
	i.v.	Not performed	0.05

*The doses are expressed as the base except in the mouse and rat MLD data, where they are expressed as brimonidine tartrate.
 **The data from additional single dose oral studies of 0.2% and 0.5% solutions of brimonidine tartrate in mice and rats showed that the oral MLD is greater than 10 mg/kg.

The most frequently observed clinical signs in the acute/single dose toxicity studies were primarily due to the exaggerated pharmacological hypotensive effect of the compound. These signs included: sedation, ataxia, prostration, ptosis, reduced/loss of blink reflex, opacification of the cornea, hypotension, bradycardia, hypothermia, respiratory depression, respiratory arrest and circulatory collapse. The ocular changes were seen only after doses at or above the MLD.

Long-term Toxicity

Long-term toxicity studies with brimonidine tartrate in various concentrations using mice, rats, rabbits, dogs and monkeys were conducted for durations of up to one year. The most notable effects seen in these studies were related to the known pharmacological effect of brimonidine.

Brimonidine was administered in repeated oral doses to mice (3 studies – 12 to 13 weeks), rats (6 studies – 6 days to 1 year), dogs (2 studies – 4 to 14 weeks) and monkeys (2 studies – 1 year each). It was also administered ocularly to rabbits (2 studies – 1 and 6 months), dogs (1 study - 4 weeks) and

monkeys (1 study - 1 year). There were no observable adverse effects in oral dosing of mice at approximately 145 times the recommended ocular human dose, rats at approximately 70 times the recommended ocular human dose, rabbits at approximately 22 times the recommended ocular human dose, dogs at approximately 50 times the recommended ocular human dose, and monkeys at approximately 30 times the recommended ocular human dose. Dosage levels of approximately 295 times greater than those recommended for human ocular use showed toxic effects that were consistent with the pharmacological class of the compound.

Chronic oral dosing studies were performed at extreme levels of approximately 2650 times the recommended human ocular dose. At these extreme doses, mice showed goblet cell hyperplasia and depletion in the rectum and colon, hypertrophy of the tunica muscularis of small and large intestine, and hyperplasia of the non-glandular epithelium of the stomach. Rats dosed orally at approximately 1330 times the human ocular dose, showed thickening of muscularis mucosa of small intestine, and a dose related incidence of ileal intussusception was observed in all rats, but no associated lesions or morphological changes were observed. Evidence of toxicity characterised by decreased body weight gain and/or decreased food consumption was often seen at the higher oral doses in the mouse, rat and monkey. The most notable effects seen in the subacute studies was an exaggerated pharmacological effect characterised by sedation, ataxia, hypoactivity, ptosis, decreased muscle tone, hypotension and bradycardia.

There were no observable adverse effects in ocular dosing of rabbits up to approximately 105 times the recommended ocular human dose, dogs up to approximately 18 times the recommended ocular human dose, and monkeys up to approximately 35 times the recommended ocular human dose.

A long-term study was conducted with Brimonidine-PURITE 0.1% or 0.2% administered to New Zealand White rabbits as 1 drop in 1 eye 3 times daily for 6 months. Both formulations were well tolerated. Slight, short term, dose-related sedation and hyperglycemia (up to 2.2-fold) were observed. These effects were considered exaggerated pharmacologic effects of alpha-2-adrenergic receptor activation. Plasma C_{max} and AUC_{0-24} hr values were increased 20 and 6 times, respectively, similar to values estimated in humans treated with 1 drop of ALPHAGAN P in both eyes TID.

Carcinogenicity: No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. Dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved 106 and 145 times, respectively, the plasma drug concentration estimated in humans treated with one drop ALPHAGAN P into both eyes TID.

Genotoxicity: Brimonidine was not mutagenic or cytogenic in a series of in vitro and in vivo studies including the Ames test, host-mediated assay, chromosomal aberration assay in CHO cells, cytogenic studies in mice and the dominant lethal assay.

Reproductive and Developmental Toxicology: No impairment of fertility and reproduction occurred in male rats when treated for 70 days prior to mating and female rats when treated for 14 days prior to mating and continuing through gestation and lactation with oral doses of brimonidine tartrate. Although blood drug levels were not determined in this study, it is estimated that the highest dose of brimonidine tartrate (0.66 mg/kg/day), achieved AUC values 60 times those seen in humans treated with 1 drop ALPHAGAN P in both eyes TID.

Teratogenicity studies have been performed in rats and rabbits. Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. The highest doses of brimonidine tartrate in rats (1.65 mg /kg/day) and rabbits (3.33 mg/kg/day) achieved AUC values 258 and 17-fold higher, respectively, than similar values estimated in

humans treated with ALPHAGAN P 1 drop in both eyes TID.

After oral dosing of ¹⁴C-brimonidine in pregnant rats, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent, producing ¹⁴C-brimonidine concentrations in fetal blood that were 10-27% of that in maternal blood. Brimonidine was predominant in the placenta, uterus, and fetal liver but not in the maternal liver.

The reproductive capabilities (survival, development, and behavior), of F1 and F2 generation rats were not affected when brimonidine tartrate was administered orally to F0 generation rats from gestation, day 16, through lactation, day 20. Although blood drug levels were not determined in this study, the high dose of brimonidine tartrate (0.66 mg/kg/day) was estimated to achieve AUC values that were 60-fold higher than similar values estimated in humans treated with ALPHAGAN P 1 drop in both eyes TID.

There were no treatment-related reproductive and teratological effects observed in the F1 rat pup group, although a reduction in body weight was observed at a dose level of 1.65 mg base/kg/day, after 14 days. Dose related reduction in body weight gains were observed in rat dams at dose levels of 0.66 and 1.65 mg base/kg/day after 15 days.

In one rabbit study, body weight gain and food consumption in the low and mid-dose groups was comparable to the control group throughout the study. Spontaneous abortions occurred in two of eight rabbits at the 3.3 mg base/kg/day level (gestation day 21 or 23), and may have been the result of the exaggerated pharmacological effects observed at this level. No abortions occurred at the 0.165 or 0.66 mg base/kg/day level. Maternal necropsy was generally unremarkable. There was no evidence of treatment-related embryotoxicity, fetal toxicity, or teratogenicity at dosage levels up to 3.3 mg base/kg/day (approximately 980 times the recommended human ocular dose). In another study involving 20 rabbit dams, dosed orally up to 2.64 mg base/kg/day, no adverse effects were observed other than a decrease in weight gain during the dosing period, and no treatment related embryolethal or teratogenic effects were observed.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrALPHAGAN P®

brimonidine tartrate ophthalmic solution

Read this carefully before you start taking **ALPHAGAN P** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **ALPHAGAN P**.

What is ALPHAGAN P used for?

- ALPHAGAN P eye drops are used to control intraocular pressure in adult patients with:
 - chronic open-angle glaucoma (a condition that causes damage to the optic nerve of your eye).
 - ocular hypertension (high pressure in the eye).

How does ALPHAGAN P work?

ALPHAGAN P is an eye drop solution that reduces the amount of fluid flowing into the eye and increases the amount of fluid flowing out of the eye. This reduces the pressure inside the eye. It contains a preservative.

What are the ingredients in ALPHAGAN P?

Medicinal ingredient: brimonidine tartrate

Non-medicinal ingredients: 0.005% w/v PURITE® as preservative, boric acid, calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, purified water with hydrochloric acid or sodium hydroxide to adjust the pH, sodium borate decahydrate, sodium carboxymethylcellulose and sodium chloride.

ALPHAGAN P comes in the following dosage forms:

Ophthalmic solution, 0.15% w/v

Do not use ALPHAGAN P if:

- you are allergic to brimonidine tartrate, any of the other ingredients or to any component of the ALPHAGAN P container (See **What are the ingredients in ALPHAGAN P?**).
- you are receiving monoamine oxidase (MAO) inhibitor therapy (used to treat depression).
- ALPHAGAN P should not be used in children under the age of 2 years.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ALPHAGAN P. Talk about any health conditions or problems you may have, including if you:

- are breastfeeding a baby, pregnant or intend to become pregnant.
- have or have had heart and blood vessel problems.
- have or have had circulation problems which make the toes and fingers numb and pale. This is called Raynaud's phenomenon.
- have or have had low blood pressure.
- are taking or intend to take other medicines. This is particularly important if you are taking medicine to lower blood pressure or to treat heart disease.
- have or have had liver problems.
- have or have had kidney problems.
- have or have had depression.
- have or have had eye surgery.
- develop an eye condition due to infection or injury.
- wear contact lenses. Lenses should be removed before using ALPHAGAN P and kept out for 15 minutes after use.

Other warnings you should know about:

Immediately tell your healthcare professional if you:

- have or have had eye surgery.
- develop an eye condition due to infection or injury.

Ask your healthcare professional for their advice on whether you should continue to use the ALPHAGAN P bottle.

Driving and using machines:

ALPHAGAN P may cause drowsiness and fatigue or blurred vision. Do not drive, use heavy machinery or participate in dangerous activities or activities requiring you to be alert, until these conditions have passed.

Children (2-18 years of age):

The use of ALPHAGAN P is currently **not recommended** in children, as several serious side effects have been reported with the use of brimonidine tartrate ophthalmic solution 0.2% in children.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with ALPHAGAN P:

- antihypertensives (medicines used to treat high blood pressure).
- cardiac glycoside (medicine used to treat heart failure and irregular heartbeats).

- central nervous system depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics).
- clonidine (medicine used to treat high blood pressure and attention deficit hyperactivity disorder [ADHD]).
- heart and blood pressure medications such as alpha-agonists.
- medication such as beta-blockers (ophthalmic and/or systemic), used to treat high blood pressure and irregular heartbeats).
- tricyclic antidepressants (medicines used to treat depression).

How to take ALPHAGAN P:

- You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.
- ALPHAGAN P contains a preservative called PURITE. If you wear contact lenses, remove them before using ALPHAGAN P. Wait 15 minutes after using the drops before you put your lenses back in.
- Always use ALPHAGAN P exactly as your healthcare professional has told you to.
- If you use ALPHAGAN P with other eye drops, wait at least five minutes between putting in ALPHAGAN P and the other drops.
- To help prevent infections, do not let the tip of the bottle touch your eye or anything else. Put the cap back on and close the bottle immediately after you have used it.

Follow the steps below to help you use ALPHAGAN P properly:

1. Wash your hands. Tilt your head back and look at the ceiling. (See image 1)
2. Gently pull down the lower eyelid to create a small pocket. (See image 2)
3. Turn the bottle upside down and squeeze it gently to release one drop into the eyelid pocket. If a drop misses your eye, try again. (See image 3)
4. Let go of the lower lid and close your eye for 30 seconds. (See image 4)



5. Repeat steps 1 – 4 in the other eye if both eyes need treatment.

Usual dose:

Following the instructions for use above, put one drop of ALPHAGAN P in the affected eye, three times daily, about 8 hours apart.

Overdose:

If you accidentally use too many drops, just go back to your regular three times a day dosing the next

day. If you have any concerns, talk to your doctor or pharmacist.

If you think you, or a person you are caring for, have taken too much ALPHAGAN P, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you forget to apply your eye drops at your normal time, simply apply them as soon as you remember. Then go back to the original schedule as directed by your healthcare professional. Don't try to catch up on missed drops by applying more than one dose at a time.

What are possible side effects from using ALPHAGAN P?

These are not all the possible side effects you may have when taking ALPHAGAN P. If you experience any side effects not listed here, tell your healthcare professional.

- a feeling that something is in your eye
- allergic reaction
- blurred vision
- burning and stinging of the eye
- constriction of eye's pupil
- depression
- dizziness
- drowsiness
- dry eyes
- dryness of the mouth
- eye and eyelid swelling
- eye allergy
- eye pain
- eyesight decrease
- eye discharge
- eye irritation
- fainting
- feeling weak
- headache
- inflammation of the surface of the eye
- inflammation of the eye's pupil
- itchy eyes and eyelids
- light sensitivity
- red eyes and eyelids
- skin reaction
- small bumps on the eye surface
- sticky eyes
- stuffy or runny nose
- swelling of eye's pupil

- visual disturbance
- watery eyes

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNCOMMON			
Bradycardia (abnormally slow heartbeat)		✓	
Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up)		✓	
Tachycardia (abnormally fast heartbeat): dizziness, light headedness, shortness of breath, racing heart		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

ALPHAGAN P should be stored in the original container at 15 to 25°C. Discard unused solution at the end of treatment.

Do not use the drops after the expiry date (marked “Exp”) on the bottle and the box.

Keep out of reach and sight of children.

If you want more information about ALPHAGAN P:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer's website www.abbvie.ca, or by calling 1-888-704-8271.

This leaflet was prepared by AbbVie Corporation.

Last Revised AUG 25, 2022

© 2022 AbbVie. All rights reserved.

ALPHAGAN P and its design are trademarks of AbbVie Corporation.